SCHEMBL3741758

SCHEMBL3741758

COC(=O)c1cc(OC)c2ccccc2c1OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.60
ALDH1A1 P00352 5/20 0.60
HPGD P15428 3/20 0.60
NPSR1 Q6W5P4 2/20 0.60
POLB P06746 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.51
GAA P10253 4/20 0.49
HSD17B10 Q99714 5/20 0.49
MAPK1 P28482 3/20 0.49
MAPT P10636 2/20 0.49
USP2 O75604 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
PLK1 P53350 1/20 0.47
DHODH Q02127 1/20 0.46
TSHR P16473 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NR4A2 P43354 1/20 0.45
CREBBP Q92793 1/20 0.45
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7677649 0.87 KDM4E (0.57) KDM4EALDH1A1HPGDNPSR1POLB
SCHEMBL976330 0.85 KDM4E (0.57) KDM4EALDH1A1HPGDNPSR1POLB
SCHEMBL406268 0.85 HTT (0.49) KDM4EALDH1A1HPGDNPSR1POLB
SCHEMBL8586325 0.83 KDM4E (0.45) KDM4EALDH1A1HPGDNPSR1POLB
SCHEMBL10892729 0.83 KDM4E (0.45) KDM4EALDH1A1HPGDNPSR1L3MBTL1
SCHEMBL17240274 0.83 MAPT (0.50) KDM4EALDH1A1HPGDNPSR1POLB
SCHEMBL20123231 0.83 KDM4E (0.52) KDM4EALDH1A1HPGDNPSR1POLB
SCHEMBL2131809 0.82 KDM4E (0.59) KDM4EALDH1A1HPGDNPSR1
SCHEMBL8966782 0.82 KDM4E (0.59) KDM4EALDH1A1HPGDNPSR1POLB
SCHEMBL5963042 0.81 HMGCR (0.53) KDM4EALDH1A1HPGDNPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4290637-A1 METAL M-AIR BATTERY CELL COMPRISING AN ORGANIC MULTI REDOX MEDIATOR COMPOUND AS SOLUBLE ORGANIC CATALYST TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) 2023-12-13 EP disclosed
EP-4290637-A1 METAL M-AIR BATTERY CELL COMPRISING AN ORGANIC MULTI REDOX MEDIATOR COMPOUND AS SOLUBLE ORGANIC CATALYST TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) 2023-12-13 EP disclosed
US-20230086413-A1 PHOTORADICAL POLYMERIZABLE COMPOSITION AIR WATER PERFORMANCE CHEMICAL INC. (JP) 2023-03-23 US disclosed
EP-2203161-B1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF UNIV INDIANA RES & TECH CORP (US) 2018-05-09 EP disclosed
EP-2203161-B1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF UNIV INDIANA RES & TECH CORP (US) 2018-05-09 EP disclosed
US-9089605-B2 Quinone derivatives, pharmaceutical compositions, and uses thereof INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-07-28 US disclosed
US-9089605-B2 Quinone derivatives, pharmaceutical compositions, and uses thereof INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-07-28 US disclosed
US-9089605-B2 Quinone derivatives, pharmaceutical compositions, and uses thereof INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-07-28 US disclosed
US-20100297113-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF PURDUE RESEARCH FOUNDATION 2010-11-25 US disclosed
US-20100297113-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF PURDUE RESEARCH FOUNDATION 2010-11-25 US disclosed
US-7304046-B2 Phosphoramide compounds PURDUE RESEARCH FOUNDATION (US) 2007-12-04 US disclosed
US-7304046-B2 Phosphoramide compounds PURDUE RESEARCH FOUNDATION (US) 2007-12-04 US disclosed
US-20040176332-A1 Phosphoramide compounds PURDUE RESEARCH FOUNDATION 2004-09-09 US disclosed
US-6656926-B2 For therapy and prophylaxis of cancer PURDUE RESEARCH FOUNDATION 2003-12-02 US disclosed
US-20030008850-A1 For therapy and prophylaxis of cancer NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-01-09 US disclosed
EP-0549366-B1 Thiazolidine compounds containing a quinone group, their preparation and their therapeutic uses SANKYO CO (JP) 1998-04-15 EP disclosed
EP-0549365-B1 Thiazolidine compounds, their preparation and their therapeutic uses SANKYO CO (JP) 1995-08-09 EP disclosed
US-5338855-A Treating diabetes or hyperlipemia SANKYO COMPANY, LIMITED (JP) 1994-08-16 US disclosed
EP-0549366-A1 Thiazolidine compounds containing a quinone group, their preparation and their therapeutic uses Sankyo Company Limited (JP) 1993-06-30 EP disclosed
EP-0549365-A1 Thiazolidine compounds, their preparation and their therapeutic uses Sankyo Company Limited (JP) 1993-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297113-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF APEX1, NQO1, REV1 KDM4E 2642/4885ALDH1A1 210/4885HPGD 288/4885
US-20040176332-A1 Phosphoramide compounds RB1, RRM2B, RRM1 KDM4E 3140/4885ALDH1A1 1067/4885HPGD 3800/4885
US-20030008850-A1 For therapy and prophylaxis of cancer BRCA1, RRM2B, FOLR1 KDM4E 3105/4885ALDH1A1 27/4885HPGD 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.